Evidence mapPaperPMID 39337436Full record

ReviewInternational journal of molecular sciences2024

Significance of Programmed Cell Death Pathways in Neurodegenerative Diseases.

Dong Guo, Zhihao Liu, Jinglin Zhou, Chongrong Ke, Daliang Li

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Gender-specific gene profiling inIBRO neuroscience reports · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Non-canonical cell death in neurodegeneration: emerging mechanisms and therapeutic Frontiers.Apoptosis : an international journal on programmed cell death · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Programmed cell death pathways in huntington's disease: spotlight on ferroptosis and pyroptosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dong GuoCollege of Life Science, Fujian Normal University Qishan Campus, Fuzhou 350117, China.ORCID 0009-0005-4403-0804
Zhihao LiuCollege of Life Science, Fujian Normal University Qishan Campus, Fuzhou 350117, China.ORCID 0009-0001-4355-9723
Jinglin ZhouCollege of Life Science, Fujian Normal University Qishan Campus, Fuzhou 350117, China.ORCID 0009-0009-8164-7044
Chongrong KeCollege of Life Science, Fujian Normal University Qishan Campus, Fuzhou 350117, China.
Daliang LiCollege of Life Science, Fujian Normal University Qishan Campus, Fuzhou 350117, China.ORCID 0000-0002-1717-9073

Funding

Joint Funds for the innovation of science and Technology, Fujian province 2023Y9415
6 · The paper itself

Abstract

Programmed cell death (PCD) is a form of cell death distinct from accidental cell death (ACD) and is also referred to as regulated cell death (RCD). Typically, PCD signaling events are precisely regulated by various biomolecules in both spatial and temporal contexts to promote neuronal development, establish neural architecture, and shape the central nervous system (CNS), although the role of PCD extends beyond the CNS. Abnormalities in PCD signaling cascades contribute to the irreversible loss of neuronal cells and function, leading to the onset and progression of neurodegenerative diseases. In this review, we summarize the molecular processes and features of different modalities of PCD, including apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis, and other novel forms of PCD, and their effects on the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), multiple sclerosis (MS), traumatic brain injury (TBI), and stroke. Additionally, we examine the key factors involved in these PCD signaling pathways and discuss the potential for their development as therapeutic targets and strategies. Therefore, therapeutic strategies targeting the inhibition or facilitation of PCD signaling pathways offer a promising approach for clinical applications in treating neurodegenerative diseases.

Indexed as

ApoptosisNeurodegenerative DiseasesSignal TransductionAnimalsFerroptosisHumansNeuronsapoptosisneurodegenerative diseases (NDDs)programmed cell death

Identifiers

PMID39337436
PMCPMC11432010

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.